FGF10 protects against particulate matter (PM)-induced lung injury via regulation of endoplasmic reticulum stress

Qiangqiang Shi1, Qiang Wang1, Li Liu1

  • 1Key Laboratory of Interventional Pulmonology of Zhejiang Province, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.

Insights

Fibroblast growth factor 10 (FGF10) shows therapeutic potential for particulate matter (PM)-induced lung injury. FGF10 treatment protects lungs by reducing endoplasmic reticulum (ER) stress and inflammation via ERK1/2 and PI3K/AKT signaling pathways.

Area of Science:

  • Pulmonary Medicine
  • Cell Biology
  • Molecular Biology

Background:

  • Particulate matter (PM) exposure causes lung diseases via oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum (ER) stress.
  • No effective therapies currently exist for PM-induced lung diseases.
  • Fibroblast growth factor 10 (FGF10) is a growth factor involved in tissue repair and has therapeutic potential.

Purpose of the Study:

  • To investigate the mechanism by which FGF10 regulates ER stress in PM-induced lung injury.
  • To evaluate the therapeutic potential of FGF10 for PM-induced lung damage.

Main Methods:

  • In vivo studies using animal models of PM-induced lung injury.
  • In vitro experiments with human bronchial epithelial cells exposed to PM and FGF10.
  • Analysis of ER stress markers (GRP78, CHOP) and inflammatory cytokines.
  • Assessment of signaling pathways (ERK1/2, PI3K/AKT) using inhibitors.

Main Results:

  • FGF10 treatment attenuated PM-induced lung injury in vivo, reducing ER stress markers GRP78 and CHOP.
  • In vitro, FGF10 sustained bronchial epithelial cell proliferation and reduced inflammatory cytokine secretion.
  • Inhibitors of ERK1/2 and PI3K/AKT signaling pathways largely blocked FGF10's protective effects on ER stress.

Conclusions:

  • FGF10 protects against PM-induced lung injury by regulating ER stress.
  • The protective mechanism involves the activation of ERK1/2 and PI3K/AKT signaling pathways.
  • FGF10 represents a promising therapeutic candidate for PM-induced lung diseases.